73.65
-0.40 (-0.54%)
| Previous Close | 74.05 |
| Open | 74.87 |
| Volume | 470,325 |
| Avg. Volume (3M) | 1,115,526 |
| Market Cap | 6,395,858,432 |
| Price / Sales | 650.22 |
| Price / Book | 13.23 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | -4.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 1.0 |
| Average | -2.00 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURROWS SCOTT L | - | 70.54 | -7,500 | -529,050 |
| SLOAN SHELDON | - | 73.52 | -8,333 | -612,642 |
| TURTLE CAMERON | - | 70.54 | -15,000 | -1,058,100 |
| Aggregate Net Quantity | -30,833 | |||
| Aggregate Net Value ($) | -2,199,792 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 71.53 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SLOAN SHELDON | Officer | 03 Jun 2026 | Automatic sell (-) | 8,333 | 73.52 | 612,642 |
| SLOAN SHELDON | Officer | 03 Jun 2026 | Option execute | 8,333 | - | - |
| BURROWS SCOTT L | Officer | 01 Jun 2026 | Automatic sell (-) | 7,500 | 70.54 | 529,050 |
| BURROWS SCOTT L | Officer | 01 Jun 2026 | Option execute | 7,500 | - | - |
| TURTLE CAMERON | Officer | 01 Jun 2026 | Automatic sell (-) | 15,000 | 70.54 | 1,058,100 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |